Abstract
Dexamethasone (DEX) is a potent synthetic member of the glucocorticoid class of steroid drugs that has anti-inflammatory and immunosuppressant effects. It is 25 times more potent than cortisol in its glucocorticoid effect, while having a minimal mineralocorticoid effect.Due to the hydrophobicity and short half-life of the drug, high doses are required to maintain its therapeutic level in the blood plasma which has undesirable side effects.Therefore, a new drug delivery system capable of overcoming the drawbacks associated with dexamethasone is required at present.The present study is aimed at developing an extended release carrier for DEX using montmorillonite (Mt) and polylactic-co-glycolic acid (PLGA) nanocomposites suitable for oral administration. The synthesized clay polymer nanocomposites (CPN) were characterized with respect to morphology, particle size, physical status etc. The in-vitro drug release behavior of DEX from Mt–PLGA nanocomposites and PLGA particles in simulated gastrointestinal fluids has been investigated. In-vitro drug release profiles of CPN in simulated gastrointestinal fluid indicate an extended release of DEX as compared to DEX–PLGA particles and pure DEX.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
